In May, the Food and Drug Administration approved tirzepatide—which patients inject under their skin weekly—to treat type 2 diabetes, because in clinical trials it cut hemoglobin A1c levels (a long-term measure of blood sugar) even more than taking insulin. The FDA has not yet approved tirzepatide for weight loss. But that may soon happen.